Sutro Biopharma, Inc. (STRO:NASDAQ) closed at $9.83 on November 3, 2026, up 7.91% on the day. The stock trades 77.6% below its 52-week high of $43.85 and 37.5% above its 52-week low of $7.15. Over the past year, it lost 17.2%. Sutro Biopharma, Inc. is part of the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)).
In 252 trading sessions since October 31, 2025, STRO closed higher on 116 days (46%). Its best day was December 3, 2025 (+19.18%) and its worst was October 13, 2026 (-17.09%). The stock moved 10% or more in a single session 16 times. It opened at least 5% above the previous day's high 3 times.
Sutro Biopharma Inc is a clinical stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.
Find more stocks like STRO with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.